Ibuprofen is a nonsteroidal anti-inflammatory drug (NSAID) sold over the counter as Advil and Motrin IB and as higher-strength prescription tablets. It treats pain, fever, menstrual cramps and arthritis. It is one of the most common drugs used around training, mostly for sore muscles and minor injuries.
The single most important fact is that ibuprofen is not risk-free just because it is sold over the counter. The prescription label carries a boxed warning for heart attack and stroke and for stomach and intestinal bleeding. The OTC Drug Facts label carries the same two warnings in plain language. Ibuprofen can also reduce kidney blood flow, and it can block the heart-protective effect of low-dose aspirin.
This page summarizes what the FDA labels, the clinical trials and the training studies report, including studies on muscle growth where the results disagree. It is for education only and is not medical advice.
| Property | Detail |
|---|---|
| Drug class | Nonsteroidal anti-inflammatory drug (NSAID); (±)-2-(p-isobutylphenyl) propionic acid |
| Brands | Advil, Motrin IB (OTC); generic prescription ibuprofen tablets |
| Route | Oral tablets, caplets and gel caplets |
| Strengths | 200 mg (OTC); 400, 600 and 800 mg (prescription) |
| Labeled OTC dose | 200 mg every 4–6 h, 400 mg if needed; no more than 6 tablets (1,200 mg) in 24 h unless directed by a doctor |
| Labeled Rx dose | 400 mg every 4–6 h for pain; 1,200–3,200 mg/day for arthritis; maximum 3,200 mg/day |
| Half-life (Rx label) | 1.8–2.0 h; peak blood levels 1–2 h after a dose |
| Boxed warning (Rx) | Cardiovascular thrombotic events (heart attack, stroke) and serious GI bleeding, ulceration and perforation |
| WADA status | Not on the 2026 Prohibited List |
What it is
Ibuprofen’s chemical name is 2-[4-(2-methylpropyl)phenyl]propanoic acid, formula C₁₃H₁₈O₂, molecular weight 206.28 g/mol (PubChem CID 3672). The prescription label describes it as the racemic (±) form, a white powder that barely dissolves in water (ibuprofen tablets label, DailyMed).
The label states that ibuprofen relieves pain, fever and inflammation, and that its mode of action “may be related to prostaglandin synthetase inhibition.” Prostaglandin synthetase is the cyclooxygenase (COX) enzyme. Prostaglandins are local signaling molecules involved in pain, fever and inflammation. The label also notes that in some patients they help keep blood flowing to the kidneys.
Ibuprofen is a “traditional” NSAID. It is not one of the COX-2-selective drugs (coxibs) such as celecoxib, and large trial pooling treats the two groups separately (CNT Collaboration, Lancet 2013). Its action at platelet COX-1 is what lets it interfere with aspirin (see Interactions below).
Exercising skeletal muscle also makes prostaglandins, and these act locally on muscle protein metabolism (Trappe & Liu, J Appl Physiol 2013). This is the reason researchers have asked whether ibuprofen could change how muscle adapts to resistance training.
Pharmacokinetics
From the prescription label (DailyMed):
| Parameter | Label value |
|---|---|
| Absorption | Rapid; peak serum levels 1–2 h after a dose |
| Dose proportionality | Linear up to 800 mg single doses; less than proportional above 800 mg |
| Effect of food | Taken right after a meal, absorption is slower but the total amount absorbed is not appreciably reduced |
| Serum half-life | 1.8–2.0 h |
| Accumulation | No evidence of drug accumulation or enzyme induction |
| Elimination | Rapidly metabolized; excretion virtually complete 24 h after the last dose |
| Urinary recovery (24 h) | 45–79% of the dose, mainly as two metabolites (A, 25%; B, 37%); about 1% as free ibuprofen and 14% as conjugated ibuprofen |
The short half-life is why both labels use dosing every 4–6 hours.
Approved medical use
| Item | OTC (Drug Facts, e.g. Advil) | Prescription tablets |
|---|---|---|
| Uses | Temporary relief of minor aches and pains (headache, toothache, backache, menstrual cramps, the common cold, muscular aches, minor arthritis pain); temporary fever reduction | Signs and symptoms of rheumatoid arthritis and osteoarthritis; mild to moderate pain; primary dysmenorrhea (menstrual pain) |
| Strength | 200 mg | 400, 600, 800 mg |
| Dose | 1 tablet every 4–6 h; 2 tablets if 1 does not work | Pain: 400 mg every 4–6 h. Arthritis: 400, 600 or 800 mg three or four times daily (1,200–3,200 mg/day) |
| Daily limit | 6 tablets in 24 h unless directed by a doctor | Do not exceed 3,200 mg/day |
| Duration limit | Stop and ask a doctor if pain lasts more than 10 days or fever more than 3 days | Lowest effective dose for the shortest duration |
Sources: Advil Drug Facts, DailyMed; ibuprofen tablets label, DailyMed.
Two label details are worth noting. For pain, doses above 400 mg were no more effective than 400 mg in controlled trials. For arthritis, patients on 3,200 mg/day did not show a better average response than those on 2,400 mg/day.
What the research shows
Muscle protein synthesis after one bout of exercise
In a placebo-controlled study, 24 young men did a hard bout of eccentric (lowering-phase) knee-extension exercise and then took ibuprofen 1,200 mg/day, acetaminophen 4,000 mg/day or placebo (Trappe et al., Am J Physiol Endocrinol Metab 2002).
| Group | Change in muscle protein synthesis 24 h after exercise |
|---|---|
| Placebo | +76% (significant) |
| Ibuprofen 1,200 mg/day | +35% (not significant) |
| Acetaminophen 4,000 mg/day | +22% (not significant) |
Neither drug changed muscle soreness ratings, creatine kinase (a marker of muscle damage) or whole-body protein breakdown compared with placebo. This acute result led to the concern that regular ibuprofen use could blunt muscle growth over time. The training trials below tested that directly, and they do not agree with each other.
Resistance training trials
| Study | Population, design | Drug and dose | Duration | Muscle size | Strength |
|---|---|---|---|---|---|
| Krentz 2008 | 18 young adults; each person’s two arms randomized to ibuprofen or placebo | Ibuprofen 400 mg after training | 6 wk | No difference (biceps thickness) | No difference (1RM curl) |
| Trappe 2011 | 36 older adults (mean age 64–67 years); placebo-controlled | Ibuprofen 1,200 mg/day or acetaminophen 4,000 mg/day | 12 wk | Greater with drugs: ibuprofen +10.9%, acetaminophen +12.5%, placebo +8.6% (quadriceps volume) | Greater with drugs: +19 kg with either drug vs +15 kg placebo |
| Petersen 2011 | 36 adults aged 50–70 with knee osteoarthritis; placebo-controlled | Ibuprofen (vs glucosamine or placebo) | 12 wk | No difference (muscle cross-sectional area) | Greater with ibuprofen: isometric +0.22 Nm/kg (95% CI 0.01–0.42), eccentric +0.38 Nm/kg (95% CI 0.05–0.70) vs placebo |
| Candow 2013 | 28 postmenopausal women; placebo-controlled | Ibuprofen 400 mg after training | 9 wk | No difference | No difference (leg press, chest press) |
| Dideriksen 2016 | 19 men aged 60–80; 2 wk leg cast, then 6 wk retraining with whey protein | Ibuprofen 1,200 mg/day vs placebo | 8 wk | No significant effect | No significant effect |
| Lilja 2018 | 31 adults aged 18–35; compared with low-dose aspirin, not placebo | Ibuprofen 1,200 mg/day vs aspirin 75 mg/day | 8 wk | Smaller with ibuprofen: +3.7% vs +7.5% quadriceps volume (group difference 34 cm³, p = 0.029) | Similar in the weight-stack leg (11–20%); generally smaller with ibuprofen in the flywheel leg |
| Mallinson 2025 | 17 resistance-trained young men; placebo-controlled | Diclofenac 75 mg/day (a different NSAID) | 12 wk | Greater with diclofenac: +8.6% vs +3.9% quadriceps area at 12 weeks (p = 0.038) | No difference (both about 40–50%) |
What these trials show, read exactly as published:
- Older adults (Trappe 2011). Over-the-counter doses of ibuprofen or acetaminophen did not blunt training gains. Muscle volume and strength rose more than with placebo when the analysis controlled for starting muscle size and strength.
- Young adults (Lilja 2018). Ibuprofen 1,200 mg/day roughly halved the gain in quadriceps volume compared with low-dose aspirin. Strength gains were similar with conventional weight-stack training and generally smaller with flywheel training. The comparison group took aspirin 75 mg/day, so this trial did not include a no-drug placebo arm.
- Lower doses (Krentz 2008, Candow 2013). Ibuprofen 400 mg taken after each session made no measurable difference to muscle size or strength, in young adults or in postmenopausal women.
- Trained men on a different NSAID (Mallinson 2025). Daily diclofenac produced more muscle growth than placebo, but no greater strength gain. This trial did not test ibuprofen.
Searching for a mechanism
The Karolinska group re-analyzed biopsies from its 2018 trial to find out why ibuprofen reduced growth in young adults (Lilja et al., J Appl Physiol 2023). mTOR signaling (a key muscle-growth pathway), ribosome production, satellite cell numbers (muscle stem cells), myonuclear addition and capillary growth did not differ between the ibuprofen and low-dose aspirin groups. Total RNA content rose about 14% in both groups. Muscle fiber size did not change with training or drug in the biopsy analysis. The authors concluded that these established growth regulators do not explain the smaller whole-muscle gain they saw with ibuprofen.
The debate is ongoing. The same group published a critique of the 2025 diclofenac trial titled “methodological concerns and alternative interpretations” (Mandić et al., J Physiol 2026). The diclofenac authors replied that the field has a “paucity of data” from long-term studies in healthy volunteers (Mallinson et al., J Physiol 2026).
Reviews and meta-analysis
- Schoenfeld 2012 (narrative review, not a meta-analysis). Concluded there is little reason to think occasional NSAID use harms muscle growth. Short-term regular use did not appear to impede growth in untrained people, and one study suggested a benefit. Longer-term use could be detrimental, especially in people with more growth potential, because of reported effects on satellite cells (Schoenfeld, Sports Med 2012).
- Trappe & Liu 2013 (review). Acute, animal and cell studies predicted that COX inhibitors would blunt adaptation. Chronic human trials lasting 1.5–4 months had not shown that, and showed a gain in older people (J Appl Physiol 2013). This review came before the Lilja 2018 trial.
- Lundberg & Howatson 2018 (review). Noted that NSAIDs have been reported to interfere with hypertrophy and strength gains in young people. Whether this carries over to sport performance or elite athletes was not established (Scand J Med Sci Sports 2018).
- de Oliveira 2024 (meta-analysis of acute performance). NSAIDs did not improve performance or strength immediately or 24 h after resistance exercise. At 48 h, performance (effect size −0.42, 95% CI −0.71 to −0.12) and strength (effect size −0.50, 95% CI −0.83 to −0.16) were lower with NSAIDs. Creatine kinase was unchanged at all time points (Phys Sportsmed 2024). This analysis looked at recovery from single sessions, not long-term muscle growth.
We did not find a meta-analysis that pooled long-term NSAID training trials for muscle hypertrophy. The trials above are small (17–36 participants each), differ in age, dose, drug and comparator, and point in different directions. No single conclusion fits all of them.
Side effects and risks
Boxed warning: heart attack and stroke
The prescription label states that NSAIDs increase the risk of serious cardiovascular thrombotic events, including heart attack and stroke, which can be fatal. The risk may start early in treatment and may increase with longer use. Ibuprofen is contraindicated around coronary artery bypass graft (CABG) surgery (DailyMed). The OTC label’s version reads that NSAIDs “except aspirin” increase the risk of heart attack, heart failure and stroke, and that the risk is higher above the directed dose or duration (Advil Drug Facts).
The label adds that the risk has been seen most consistently at higher doses, and that people with heart disease or its risk factors have a higher absolute risk because their baseline risk is higher.
Trial data on ibuprofen specifically:
| Source | Finding for ibuprofen |
|---|---|
| CNT Collaboration, Lancet 2013, individual data from 280 placebo-controlled and 474 head-to-head NSAID trials | Major coronary events RR 2.22 (95% CI 1.10–4.48) vs placebo. Major vascular events RR 1.44 (95% CI 0.89–2.33), not significant. Heart failure roughly doubled with all NSAIDs. The authors concluded that the vascular risk of high-dose ibuprofen was “possibly” comparable to coxibs |
| PRECISION, NEJM 2016, 24,081 arthritis patients at increased heart risk; mean ibuprofen dose about 2,045 mg/day | Cardiovascular death, heart attack or stroke: 2.7% ibuprofen, 2.5% naproxen, 2.3% celecoxib (intention to treat). Celecoxib was noninferior to ibuprofen (HR 0.85, 95% CI 0.70–1.04) |
Boxed warning: stomach and intestinal bleeding
NSAIDs can cause bleeding, ulcers and perforation of the stomach or intestines, which can be fatal and can occur at any time without warning symptoms. Older adults are at greater risk (DailyMed). From the label:
- Upper GI ulcers, gross bleeding or perforation occur in about 1% of patients treated for 3–6 months and about 2–4% of patients treated for a year.
- Only about one in five patients who develop a serious upper GI event has symptoms beforehand.
- A history of ulcer disease or GI bleeding raises the risk of a GI bleed more than 10-fold.
- Other risk factors include oral corticosteroids, anticoagulants, longer use, smoking, alcohol, older age and poor general health.
The OTC label adds age 60 or older, taking other NSAIDs, and 3 or more alcoholic drinks a day. In the CNT meta-analysis, ibuprofen raised upper GI complications about fourfold vs placebo (RR 3.97, 95% CI 2.22–7.10) (Lancet 2013).
Kidney risk
Prostaglandins help keep blood flowing to the kidneys when that flow is under strain. The label explains that in people who rely on this, an NSAID can reduce renal blood flow in a dose-dependent way and trigger overt kidney decompensation. The people at greatest risk are those with:
- impaired kidney function;
- heart failure;
- liver dysfunction;
- use of diuretics or ACE inhibitors;
- older age.
Function usually recovers after stopping. Long-term NSAID use has also caused renal papillary necrosis (death of tissue in the kidney’s inner part) and other kidney injury. The label does not recommend ibuprofen in advanced kidney disease (DailyMed). In the PRECISION trial, renal events were significantly more common with ibuprofen than with celecoxib (p = 0.004) (Nissen et al., NEJM 2016).
Endurance exercise is a related setting. In a randomized, double-blind trial during 80 km desert ultramarathons, runners took ibuprofen 400 mg every 4 hours or placebo (Lipman et al., Emerg Med J 2017). Acute kidney injury occurred in 52% on ibuprofen vs 34% on placebo (OR 2.1, 95% CI 0.9–5.1). That difference was not statistically significant, but the authors calculated that 1 extra case of kidney injury occurred for every 5.5 runners who took ibuprofen.
Blood pressure and heart failure
NSAIDs can cause new high blood pressure or worsen existing high blood pressure. They can also blunt the effect of diuretics, ACE inhibitors and angiotensin receptor blockers (ARBs). The label advises monitoring blood pressure during treatment and avoiding ibuprofen in severe heart failure unless the benefit outweighs the risk. Fluid retention and edema occur in some patients (DailyMed).
Interaction with low-dose aspirin
Low-dose aspirin inhibits platelets irreversibly, which is the basis of its use against heart attack and stroke (see Aspirin (Low-Dose)). Ibuprofen can get in the way of this (Catella-Lawson et al., NEJM 2001).
In a crossover study, ibuprofen 400 mg taken before aspirin 81 mg, or ibuprofen taken three times daily, blocked aspirin’s inhibition of platelet thromboxane and platelet aggregation. Acetaminophen, rofecoxib and diclofenac did not (Catella-Lawson et al., NEJM 2001). The authors concluded this could limit aspirin’s heart-protective effect in people at higher cardiovascular risk.
The prescription label gives these healthy-volunteer results, measured as inhibition of serum thromboxane B2 24 h after the day-6 aspirin dose (DailyMed):
| Regimen | Thromboxane inhibition |
|---|---|
| Ibuprofen 400 mg once daily, 2 h before immediate-release aspirin 81 mg | 53% (interaction) |
| Ibuprofen 400 mg once daily, 8 h before aspirin | 90.7% (smaller interaction) |
| Ibuprofen 400 mg once daily, 2 h after immediate-release aspirin | 99.2% (no interaction) |
| Enteric-coated aspirin 81 mg plus ibuprofen 400 mg three times daily | 67% (interaction) |
The label states that the timing benefit seen with immediate-release aspirin cannot be extended to enteric-coated aspirin. For people on low-dose aspirin for heart protection who need a pain reliever, it says to consider an NSAID that does not interfere, or a non-NSAID pain reliever. Taking aspirin and ibuprofen together also raises the risk of serious GI events. The OTC label tells people taking aspirin for heart attack or stroke to ask a doctor or pharmacist first, “because ibuprofen may decrease this benefit of aspirin” (Advil Drug Facts).
Other interactions
From the prescription label (DailyMed):
| Drug | What the label reports |
|---|---|
| Warfarin-type anticoagulants | GI bleeding effects are synergistic; risk of serious GI bleeding is higher than with either drug alone |
| ACE inhibitors | NSAIDs may reduce their blood-pressure-lowering effect |
| Diuretics (furosemide, thiazides) | Ibuprofen can reduce their sodium-excreting effect; watch for kidney failure |
| Lithium | In 11 healthy volunteers, minimum lithium levels rose 15% and renal lithium clearance fell 19% |
| Methotrexate | NSAIDs may increase methotrexate toxicity (based on rabbit kidney tissue data) |
| Other NSAIDs, including aspirin | Not generally recommended together because of more side effects |
Allergy, skin reactions and pregnancy
- Allergy. Ibuprofen is contraindicated in people who have had asthma, hives or allergic-type reactions after aspirin or other NSAIDs. Severe, rarely fatal reactions have been reported in such patients.
- Serious skin reactions. These include Stevens-Johnson syndrome, toxic epidermal necrolysis and DRESS (a drug reaction with fever, rash and organ involvement), which can be fatal.
- Pregnancy. Use at about 20 weeks or later can cause fetal kidney problems leading to low amniotic fluid (oligohydramnios). Use at about 30 weeks or later can cause premature closure of the ductus arteriosus (a fetal blood vessel). The label says to avoid use from about 30 weeks. The OTC label says not to use it at 20 weeks or later unless a doctor directs it.
Sources: ibuprofen tablets label; Advil Drug Facts.
Who should not use it
The labels list these groups:
- Contraindicated (Rx label): known hypersensitivity to ibuprofen; asthma or allergic reactions to aspirin or other NSAIDs; around CABG surgery.
- Do not use (OTC label): past allergic reaction to any pain reliever or fever reducer; right before or after heart surgery.
- Ask a doctor first (OTC label): stomach bleeding risk factors, history of stomach problems, high blood pressure, heart disease, liver cirrhosis, kidney disease, asthma, prior stroke, or taking a diuretic.
Legal and anti-doping status
In the US, ibuprofen 200 mg is sold over the counter under a Drug Facts label. The 400, 600 and 800 mg tablets are prescription-only (Advil Drug Facts; ibuprofen tablets label). Ibuprofen and NSAIDs as a class do not appear on the WADA 2026 Prohibited List.
Key takeaways
- Two boxed warnings, even at OTC strength. Both labels warn about heart attack and stroke and about serious stomach and intestinal bleeding. The risks rise with higher doses and longer use.
- Short-acting. The half-life is about 2 hours, which is why both labels use dosing every 4–6 hours. The OTC limit is 1,200 mg/day unless a doctor directs more, and the prescription maximum is 3,200 mg/day.
- Kidneys are sensitive to it. Risk is highest with dehydration, kidney or heart disease, diuretics, ACE inhibitors and older age. In desert ultramarathons, 52% of runners on ibuprofen vs 34% on placebo developed acute kidney injury.
- It can cancel low-dose aspirin’s effect. Taking ibuprofen before aspirin, or several times a day, blocked aspirin’s antiplatelet action in controlled studies.
- Muscle-growth evidence is mixed. Ibuprofen 1,200 mg/day halved quadriceps growth compared with low-dose aspirin in young adults. The same dose increased growth compared with placebo in older adults, and 400 mg after training had no effect in two trials.
- Small trials, no settled answer. No meta-analysis has pooled the long-term training trials. The single-session meta-analysis found no performance benefit from NSAIDs and lower strength 48 h after exercise.
Sources
- Amneal Pharmaceuticals. Ibuprofen tablets USP, 400 mg, 600 mg, 800 mg, prescribing information (revised 12/2024). DailyMed.
- Haleon US Holdings. Advil (ibuprofen tablets, 200 mg) Drug Facts label. DailyMed.
- National Center for Biotechnology Information. Ibuprofen, PubChem compound summary, CID 3672. PubChem.
- Catella-Lawson F, Reilly MP, Kapoor SC, et al. Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N Engl J Med. 2001;345(25):1809–1817. PubMed.
- Coxib and traditional NSAID Trialists’ (CNT) Collaboration; Bhala N, Emberson J, Merhi A, et al. Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials. Lancet. 2013;382(9894):769–779. PubMed.
- Nissen SE, Yeomans ND, Solomon DH, et al. Cardiovascular safety of celecoxib, naproxen, or ibuprofen for arthritis. N Engl J Med. 2016;375(26):2519–2529. PubMed.
- Lipman GS, Shea K, Christensen M, et al. Ibuprofen versus placebo effect on acute kidney injury in ultramarathons: a randomised controlled trial. Emerg Med J. 2017;34(10):637–642. PubMed.
- Trappe TA, White F, Lambert CP, et al. Effect of ibuprofen and acetaminophen on postexercise muscle protein synthesis. Am J Physiol Endocrinol Metab. 2002;282(3):E551–E556. PubMed.
- Krentz JR, Quest B, Farthing JP, et al. The effects of ibuprofen on muscle hypertrophy, strength, and soreness during resistance training. Appl Physiol Nutr Metab. 2008;33(3):470–475. PubMed.
- Trappe TA, Carroll CC, Dickinson JM, et al. Influence of acetaminophen and ibuprofen on skeletal muscle adaptations to resistance exercise in older adults. Am J Physiol Regul Integr Comp Physiol. 2011;300(3):R655–R662. PubMed.
- Petersen SG, Beyer N, Hansen M, et al. Nonsteroidal anti-inflammatory drug or glucosamine reduced pain and improved muscle strength with resistance training in a randomized controlled trial of knee osteoarthritis patients. Arch Phys Med Rehabil. 2011;92(8):1185–1193. PubMed.
- Candow DG, Chilibeck PD, Weisgarber K, et al. Ingestion of low-dose ibuprofen following resistance exercise in postmenopausal women. J Cachexia Sarcopenia Muscle. 2013;4(1):41–46. PubMed.
- Dideriksen K, Boesen AP, Kristiansen JF, et al. Skeletal muscle adaptation to immobilization and subsequent retraining in elderly men: no effect of anti-inflammatory medication. Exp Gerontol. 2016;82:8–18. PubMed.
- Lilja M, Mandić M, Apró W, et al. High doses of anti-inflammatory drugs compromise muscle strength and hypertrophic adaptations to resistance training in young adults. Acta Physiol (Oxf). 2018;222(2):e12948. PubMed.
- Lilja M, Moberg M, Apró W, et al. Limited effect of over-the-counter doses of ibuprofen on mechanisms regulating muscle hypertrophy during resistance training in young adults. J Appl Physiol (1985). 2023;134(3):753–765. PubMed.
- Mallinson JE, Taylor T, Constantin-Teodosiu D, et al. NSAID ingestion augments training-induced muscle hypertrophy and differentially affects muscle mRNA expression, but not strength gains, in trained men. J Physiol. Published online October 26, 2025. doi:10.1113/JP289542. PubMed.
- Mandić M, Gustafsson T, Lundberg TR. NSAIDs and muscle hypertrophy: methodological concerns and alternative interpretations. J Physiol. Published online February 18, 2026. doi:10.1113/JP290811. PubMed. Reply: Mallinson JE, Constantin-Teodosiu D, Constantin D, et al. J Physiol. Published online March 11, 2026. doi:10.1113/JP291133. PubMed.
- Schoenfeld BJ. The use of nonsteroidal anti-inflammatory drugs for exercise-induced muscle damage: implications for skeletal muscle development. Sports Med. 2012;42(12):1017–1028. PubMed.
- Trappe TA, Liu SZ. Effects of prostaglandins and COX-inhibiting drugs on skeletal muscle adaptations to exercise. J Appl Physiol (1985). 2013;115(6):909–919. PubMed.
- Lundberg TR, Howatson G. Analgesic and anti-inflammatory drugs in sports: implications for exercise performance and training adaptations. Scand J Med Sci Sports. 2018;28(11):2252–2262. PubMed.
- de Oliveira GM, Barcelos Andrade FA, Pereira AB, et al. Is physical performance affected by non-steroidal anti-inflammatory drugs use? A systematic review and meta-analysis. Phys Sportsmed. 2024;52(3):207–216. PubMed.
- World Anti-Doping Agency. The 2026 Prohibited List (in effect from January 1, 2026). WADA.